Implementation of a strict "No-X-Ray, simplified 2-catheter" CA approach is safe and effective in majority of the patients with SVT. This modified approach for SVTs should be prospectively validated in a multicenter study.

Current recommendations avoid the use of antiarrhythmic drugs in pregnancy and support catheter ablation (CA) due to symptomatic arrhythmias prior to pregnancy. Zero-fluoroscopy (ZF) mapping and navigation with three-dimensional electroanatomical mapping systems (3D-EAMS) allowed routine and safe non-fluoroscopic guidance of the procedure without X-ray exposure. We present the first case of a pregnant patient who underwent successful ZF CA of symptomatic pre-excitation from non-coronary cusp (NCC). A 24-year-old Caucasian pregnant without structural heart disease at the 24 th week of pregnancy was referred for CA due to three recurrences of syncope and drug-refractory palpitations associated with Wolf-Parkinson-White (WPW) syndrome. Twelve months prior to pregnancy the woman had failed radiofrequency (RF) ablation procedure in another centre for para-Hisian right-sided pathway. A 12-lead electrocardiogram (ECG) showed pre-excitation with a positive delta wave in leads I, II, aVF, V4, and V5 and a negative delta wave in lead V1, suggesting a para-Hisian accessory pathway ( Fig. 1). She was referred to our hospital for rescue CA with ZF. Our centre had at least five years of experience with the minimally invasive non-fluoroscopic imaging and navigation approach using the Ensite NavX system (St. Jude Medical, St. Paul, MN) for CA of regular supraventricular arrhythmias and idiopathic ventricular arrhythmias. A multidisciplinary consultation reached the consensus that only pre-excitation is a substrate for syncope recurrences and poses a potential risk to the foetus and mother. The right femoral vein was cannulated with a 7 F or 8 F sheath and one ablation 4 mm Gold tip catheter and one diagnostic decapolar catheter (Biotronik, Berlin, Germany) were introduced. Atrial pacing protocols demonstrated a septal accessory pathway, but no isoproterenol was given to induce tachycardia. The refractory period of the accessory pathway was 300 ms. After six failed right-sided applications right sided mapping was stopped due to frequent junctional beats and proximity of His potential recordings. Then, the right femoral artery was cannulated with an 8 F introducer, and the ablation catheter was removed using a right to left retrograde approach (Fig. 2). Finally, six RF applications (240 s) were delivered approximately in the NCC and the accessory pathway was successfully ablated (Fig. 1). The procedure time was 71 min and no fluoroscopy was used. Several ECGs and Holter monitoring confirmed no pre-excitation and arrhythmias within 14 months. The patient delivered a healthy male child at 35 weeks of gestation by Caesarean section. Both mother and child had an uneventful postoperative course. The case documents that routinely using ZF for CA may support this approach even for unfavourable locations (e.g. NCC) and not only as the last resort for several arrhythmias including WPW-syndrome in pregnant patients.

Aims  The aim of this study was to determine the contemporary use of reperfusion therapy in the European Society of Cardiology (ESC) member and affiliated countries and adherence to ESC clinical practice guidelines in patients with ST-elevation myocardial infarction (STEMI). Methods and results  Prospective cohort (EURObservational Research Programme STEMI Registry) of hospitalized STEMI patients with symptom onset <24 h in 196 centres across 29 countries. A total of 11 462 patients were enrolled, for whom primary percutaneous coronary intervention (PCI) (total cohort frequency: 72.2%, country frequency range 0–100%), fibrinolysis (18.8%; 0–100%), and no reperfusion therapy (9.0%; 0–75%) were performed. Corresponding in-hospital mortality rates from any cause were 3.1%, 4.4%, and 14.1% and overall mortality was 4.4% (country range 2.5–5.9%). Achievement of quality indicators for reperfusion was reported for 92.7% (region range 84.8–97.5%) for the performance of reperfusion therapy of all patients with STEMI <12 h and 54.4% (region range 37.1–70.1%) for timely reperfusion. Conclusions  The use of reperfusion therapy for STEMI in the ESC member and affiliated countries was high. Primary PCI was the most frequently used treatment and associated total in-hospital mortality was below 5%. However, there was geographic variation in the use of primary PCI, which was associated with differences in in-hospital mortality.

INTRODUCTION Radiofrequency ablation (RFA) of outflow tract ventricular arrhythmia (VA) that originates from the aortic cusps can be challenging. Data on long-term efficacy and safety as well as optimal technique after aortic cusp ablation have not previously been reported. OBJECTIVES This aim of the study was to determine the short-and long-term outcomes after RFA of aortic cusp VA, and to evaluate aortic valve injuries according to echocardiographic screening. PATIENTS AND METHODS This was a prospective multicenter registry (AVATAR, Aortic Cusp Ventricular Arrhythmias: Long Term Safety and Outcome from a Multicenter Prospective Ablation Registry) study. A total of 103 patients at a mean age of 56 years (34-64) from the "Electra" Registry (2005-2017) undergoing RFA of aortic cusps VA were enrolled. The following 3 ablation techniques were used: zero-fluoroscopy (ZF; electroanatomical mapping [EAM] without fluoroscopy), EAM with fluoroscopy, and conventional fluoroscopy-based RFA. Data on clinical history, complications after RFA, echocardiography, and 24-hour Holter monitoring were collected. The follow-up was 12 months or longer. RESULTS There were no major acute cardiac complications after RFA. In one case, a vascular access complication required surgery. The median (interquartile range [IQR]) procedure time was 75 minutes (IQR, 58-95), median follow-up, 32 months (IQR, 12-70). Acute and long-term procedural success rates were 93% and 86%, respectively. The long-term RFA outcomes were observed in ZF technique (88%), EAM with fluoroscopy (86%), and conventional RFA (82%), without differences. During long-term follow-up, no abnormalities were found within the aortic root. CONCLUSIONS Ablation of VA within the aortic cusps is safe and effective in long-term follow-up. The ZF approach is feasible, although it requires greater expertise and more imaging modalities.

No abstract